Holen Sie sich die Stockscreener-App
46.20
2.59%
-1.21
Handel nachbörslich:
46.20
Schlusskurs vom Vortag:
$47.41
Offen:
$46.96
24-Stunden-Volumen:
817.39K
Relative Volume:
0.56
Marktkapitalisierung:
$1.96B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-63.78M
KGV:
-17.24
EPS:
-2.68
Netto-Cashflow:
$-53.91M
1W Leistung:
-6.17%
1M Leistung:
-15.90%
6M Leistung:
+373.64%
1J Leistung:
+204.62%
1-Tages-Spanne:
$45.03
$46.96
1-Wochen-Bereich:
$45.03
$50.11
52-Wochen-Spanne:
$7.575
$63.06
Celcuity Inc Stock (CELC) Company Profile
Firmenname
Celcuity Inc
Sektor
Branche
Telefon
763-392-0767
Adresse
16305 36TH AVENUE N, MINNEAPOLIS, MN
Vergleichen Sie CELC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CELC
Celcuity Inc
|
46.20 | 1.95B | 0 | -63.78M | -53.91M | -2.68 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Celcuity Inc Stock (CELC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-22 | Eingeleitet | Guggenheim | Buy |
| 2025-07-01 | Fortgesetzt | Stifel | Buy |
| 2024-07-22 | Eingeleitet | Leerink Partners | Outperform |
| 2024-02-22 | Eingeleitet | Stifel | Buy |
| 2023-12-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-10-08 | Eingeleitet | Canaccord Genuity | Buy |
| 2021-09-07 | Eingeleitet | Jefferies | Buy |
| 2021-07-29 | Eingeleitet | Cowen | Outperform |
| 2021-07-27 | Eingeleitet | Needham | Buy |
| 2021-01-28 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-24 | Bestätigt | H.C. Wainwright | Buy |
| 2020-05-11 | Fortgesetzt | Craig Hallum | Buy |
| 2018-11-20 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Celcuity Inc Aktie (CELC) Neueste Nachrichten
Will Celcuity Inc. stock benefit from AI adoptionWeekly Trade Summary & Community Consensus Picks - newser.com
Candlestick signals on Celcuity Inc. stock todayJuly 2025 Earnings & Trade Opportunity Analysis Reports - newser.com
Celcuity (NASDAQ:CELC) Stock Price Down 5.1%What's Next? - MarketBeat
Historical volatility pattern of Celcuity Inc. visualizedJuly 2025 PostEarnings & Weekly Market Pulse Alerts - newser.com
Celcuity's (CELC) Sell (D-) Rating Reaffirmed at Weiss Ratings - MarketBeat
Celcuity: Blink And You Missed It (NASDAQ:CELC) - Seeking Alpha
Celcuity's VIKTORIA-1 Results To Anchor ESMO Presentation; NDA Submission Underway - RTTNews
Short interest data insights for Celcuity Inc.Quarterly Investment Review & Weekly Watchlist of Top Performers - newser.com
What data driven models say about Celcuity Inc.’s futureTrade Exit Report & Safe Capital Growth Tips - newser.com
Multi asset correlation models including Celcuity Inc.Weekly Loss Report & Weekly Sector Rotation Insights - newser.com
Celcuity Inc. stock trend forecastStop Loss & Daily Stock Trend Reports - newser.com
Long term hold vs stop loss in Celcuity Inc.Layoff News & Daily Growth Stock Investment Tips - newser.com
Can technical indicators confirm Celcuity Inc.’s reversal2025 Trade Ideas & Daily Oversold Stock Bounce Ideas - newser.com
Should FDA Real-Time Review of Gedatolisib Prompt a Closer Look From Celcuity (CELC) Investors? - simplywall.st
Needham Maintains Celcuity(CELC.US) With Buy Rating, Maintains Target Price $70 - 富途牛牛
Celcuity (NASDAQ:CELC) Given Buy Rating at Needham & Company LLC - MarketBeat
How to interpret RSI for Celcuity Inc. stock2025 Institutional Moves & Daily Stock Momentum Reports - newser.com
Celcuity (CELC): Valuing the Stock After FDA Acceptance of Gedatolisib and Major Pipeline Progress - Sahm
Celcuity Expands Credit Facility to $500 Million - MSN
Why Celcuity Inc. stock appeals to dividend seekers2025 Technical Overview & Smart Investment Allocation Insights - newser.com
Celcuity (NASDAQ:CELC) Shares Down 4.8%Here's Why - MarketBeat
3 Growth Companies With High Insider Ownership Seeing Up To 63% Revenue Growth - simplywall.st
Celcuity Inc. (CELC)’s FDA NDA for Gedatolisib Accepted Under RTOR, Accelerating Review - Insider Monkey
Certain Options of Celcuity Inc. are subject to a Lock-Up Agreement Ending on 29-SEP-2025. - MarketScreener
Certain Pre-Funded Warrants of Celcuity Inc. are subject to a Lock-Up Agreement Ending on 29-SEP-2025. - MarketScreener
Certain Common Stock of Celcuity Inc. are subject to a Lock-Up Agreement Ending on 29-SEP-2025. - MarketScreener
Craig-Hallum Remains a Buy on Celcuity (CELC) - The Globe and Mail
The Bull Case For Celcuity (CELC) Could Change Following Expanded Credit Facility and Rising Commercial Ambitions - simplywall.st
Celcuity (NASDAQ:CELC) Shares Down 5.5%Time to Sell? - MarketBeat
Celcuity to present phase 3 breast cancer trial data at ESMO congress - Investing.com Nigeria
Goldman Sachs Group Inc. Sells 28,686 Shares of Celcuity, Inc. $CELC - MarketBeat
Guggenheim initiates Celcuity stock with Buy rating on breast cancer drug potential By Investing.com - Investing.com South Africa
Guggenheim initiates Celcuity stock with Buy rating on breast cancer drug potential - Investing.com Australia
Finanzdaten der Celcuity Inc-Aktie (CELC)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.47%
1.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):